Guardant Health Unveils Major Upgrade to Guardant360® CDx Liquid Biopsy Test

Guardant Health Revolutionizes Cancer Detection with Smart Liquid Biopsy™

Guardant Health, a leading precision oncology company, has announced a major upgrade to its flagship product, the Guardant360® CDx liquid biopsy test. The enhancement introduces Smart Liquid Biopsy™ technology, which promises to significantly improve the test's ability to detect and analyze circulating tumor DNA (ctDNA) in blood samples from patients with advanced cancers 1

1

Enhanced Performance and Clinical Utility

The upgraded Guardant360 CDx test boasts improved sensitivity and specificity across all variant types. This advancement allows for the detection of genomic alterations with unprecedented accuracy, even in cases where traditional tissue biopsies may be challenging or impossible 2

2

Key improvements include:

• Enhanced detection of SNVs, indels, fusions, and amplifications
• Expanded gene panel coverage
• Improved limit of detection for certain biomarkers

Impact on Patient Care

The enhanced capabilities of the Guardant360 CDx test are expected to have a significant impact on patient care. By providing more comprehensive and accurate genomic profiling, oncologists can make more informed treatment decisions, potentially leading to improved outcomes for patients with advanced cancers 1

1

Market Leadership and Future Prospects

Guardant Health's commitment to innovation has solidified its position as a market leader in liquid biopsy technology. The company's continued investment in research and development is aimed at expanding the clinical utility of its tests and addressing unmet needs in cancer care 2

2

Related Stories

Guardant Health to Present Groundbreaking Precision Oncology Data at ESMO 2024

Precision for Medicine and SOPHiA GENETICS Partner to Enhance AI-Driven Biomarker Discovery and Clinical Trials

SOPHiA GENETICS Expands Partnership with Canadian Oncology Lab OncoHelix

Mainz Biomed Partners with Liquid Biosciences to Enhance Pancreatic Cancer Detection Using AI

Regulatory Approval and Availability

The upgraded Guardant360 CDx test has received FDA approval for its enhanced capabilities. It is now available for clinical use, offering healthcare providers and patients access to this advanced diagnostic tool 1

1

Industry Implications

This technological advancement is expected to further accelerate the adoption of liquid biopsy tests in clinical practice. As the field of precision oncology continues to evolve, innovations like Smart Liquid Biopsy™ are likely to play a crucial role in shaping the future of cancer diagnosis and treatment 2

2